Doctronic

DoctronicDoctronic
Doctronic

Doctronic

AI platform for legally renewing prescriptions in the U.S.

DR 66Speed 332021ActiveNew York, USA
Rate

About

Doctronic offers a free, anonymous AI doctor service that provides symptom-based diagnoses and treatment plans, trained on peer-reviewed medical research and validated by board-certified clinicians. Users can then connect with licensed U.S. doctors for telehealth appointments, prescriptions, lab tests, and doctor's notes, with all health history securely stored and managed. The service is available to U.S. residents and aims to provide expert medical insights and convenient access to care.
Frequently asked

What does Doctronic do?

Doctronic offers a free, anonymous AI doctor service that provides symptom-based diagnoses and treatment plans, trained on peer-reviewed medical research and validated by board-certified clinicians. Users can then connect with licensed U.S. doctors for telehealth appointments, prescriptions, lab tests, and doctor's notes, with all health history securely stored and managed. The service is available to U.S. residents and aims to provide expert medical insights and convenient access to care.

What is Doctronic's revenue?

StartupHub estimates Doctronic's annual revenue at $51.4M (range $25.5M to $104.5M, 43% confidence), based on comparable companies in the sector.

What is Doctronic's valuation?

StartupHub estimates Doctronic's effective valuation at $202.2M (range $98.9M to $433.9M, 55% confidence), based on comparable companies in the sector.

How much funding has Doctronic raised?

Doctronic has raised a total of $65M in funding. The most recent round on record is Series B.

Where is Doctronic headquartered?

Doctronic is headquartered in New York, New York, USA.

When was Doctronic founded?

Doctronic was founded in 2021.

What industry does Doctronic operate in?

Doctronic operates in Artificial Intelligence, HealthTech, Telemedicine, AI & Models, Foundation Model, Large Language Model.

Comments

No comments yet. Be the first to share your take.